Anna Maria Frezza, MD

Medical Oncologist
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Italy

Poster(s):

• (P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION

• (P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP

• (P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL

• (P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA

• (P 188) PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS

• (P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE